News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,775 Results
Type
Article (58642)
Company Profile (257)
Press Release (667854)
Multimedia
Podcasts (143)
Webinars (23)
Section
Business (204208)
Career Advice (2998)
Deals (34762)
Drug Delivery (130)
Drug Development (82197)
Employer Resources (172)
FDA (17155)
Job Trends (15266)
News (348103)
Policy (34763)
Tag
Academia (2757)
Academic (2)
Accelerated approval (17)
Adcomms (35)
Allergies (120)
Alliances (50851)
ALS (135)
Alzheimer's disease (1630)
Antibody-drug conjugate (ADC) (199)
Approvals (17160)
Artificial intelligence (410)
Autoimmune disease (48)
Automation (22)
Bankruptcy (365)
Best Places to Work (11572)
BIOSECURE Act (22)
Biosimilars (150)
Biotechnology (181)
Bladder cancer (117)
Brain cancer (43)
Breast cancer (428)
Cancer (3480)
Cardiovascular disease (304)
Career advice (2526)
Career pathing (36)
CAR-T (225)
CDC (51)
Cell therapy (609)
Cervical cancer (28)
Clinical research (67863)
Collaboration (1272)
Company closure (4)
Compensation (861)
Complete response letters (50)
COVID-19 (2862)
CRISPR (77)
C-suite (505)
Cystic fibrosis (127)
Data (3782)
Decentralized trials (2)
Denatured (43)
Depression (99)
Diabetes (416)
Diagnostics (6553)
Digital health (26)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (194)
Drug pricing (167)
Drug shortages (34)
Duchenne muscular dystrophy (183)
Earnings (85936)
Editorial (53)
Employer branding (22)
Employer resources (152)
Events (119479)
Executive appointments (936)
FDA (19381)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (1099)
Gene editing (161)
Generative AI (38)
Gene therapy (494)
GLP-1 (980)
Government (4769)
Grass and pollen (7)
Guidances (334)
Healthcare (18831)
HIV (46)
Huntington's disease (34)
IgA nephropathy (51)
Immunology and inflammation (225)
Immuno-oncology (19)
Indications (47)
Infectious disease (3080)
Inflammatory bowel disease (175)
Inflation Reduction Act (12)
Influenza (86)
Intellectual property (165)
Interviews (559)
IPO (16529)
IRA (57)
Job creations (4088)
Job search strategy (2096)
Kidney cancer (14)
Labor market (63)
Layoffs (610)
Leadership (31)
Legal (8571)
Liver cancer (87)
Longevity (12)
Lung cancer (504)
Lymphoma (250)
Machine learning (22)
Management (57)
Manufacturing (554)
MASH (119)
Medical device (13502)
Medtech (13518)
Mergers & acquisitions (19055)
Metabolic disorders (1067)
Multiple sclerosis (121)
NASH (22)
Neurodegenerative disease (181)
Neuropsychiatric disorders (51)
Neuroscience (2532)
NextGen: Class of 2025 (6575)
Non-profit (4478)
Now hiring (39)
Obesity (538)
Opinion (294)
Ovarian cancer (113)
Pain (155)
Pancreatic cancer (146)
Parkinson's disease (213)
Partnered (27)
Patents (384)
Patient recruitment (260)
Peanut (56)
People (58770)
Pharmaceutical (54)
Pharmacy benefit managers (25)
Phase I (20859)
Phase II (29634)
Phase III (22839)
Pipeline (2473)
Policy (278)
Postmarket research (2809)
Preclinical (8959)
Press Release (68)
Prostate cancer (175)
Psychedelics (50)
Radiopharmaceuticals (270)
Rare diseases (603)
Real estate (6138)
Recruiting (70)
Regulatory (24710)
Reports (47)
Research institute (2505)
Resumes & cover letters (476)
Rett syndrome (12)
RNA editing (15)
RSV (63)
Schizophrenia (123)
Series A (184)
Series B (142)
Service/supplier (14)
Sickle cell disease (75)
Special edition (25)
Spinal muscular atrophy (158)
Sponsored (39)
Startups (3762)
State (2)
Stomach cancer (17)
Supply chain (94)
Tariffs (84)
The Weekly (98)
Vaccines (1003)
Venture capital (63)
Weight loss (376)
Women's health (48)
Worklife (21)
Date
Today (79)
Last 7 days (525)
Last 30 days (2260)
Last 365 days (32276)
2025 (23010)
2024 (36233)
2023 (40920)
2022 (51979)
2021 (56248)
2020 (54306)
2019 (46585)
2018 (35338)
2017 (34126)
2016 (33868)
2015 (38939)
2014 (33749)
2013 (29176)
2012 (29271)
2011 (29708)
2010 (27800)
Location
Africa (959)
Alabama (75)
Alaska (6)
Arizona (244)
Arkansas (12)
Asia (42440)
Australia (7269)
California (8701)
Canada (2579)
China (798)
Colorado (355)
Connecticut (385)
Delaware (236)
Europe (99692)
Florida (1291)
Georgia (292)
Hawaii (3)
Idaho (55)
Illinois (712)
India (44)
Indiana (414)
Iowa (18)
Japan (275)
Kansas (113)
Kentucky (29)
Louisiana (17)
Maine (72)
Maryland (1194)
Massachusetts (6482)
Michigan (272)
Minnesota (523)
Mississippi (4)
Missouri (102)
Montana (23)
Nebraska (23)
Nevada (99)
New Hampshire (72)
New Jersey (2408)
New Mexico (30)
New York (2366)
North Carolina (1289)
North Dakota (10)
Northern California (3939)
Ohio (261)
Oklahoma (19)
Oregon (37)
Pennsylvania (1794)
Puerto Rico (14)
Rhode Island (40)
South America (1342)
South Carolina (43)
South Dakota (1)
Southern California (3357)
Tennessee (135)
Texas (1325)
United States (31902)
Utah (253)
Virginia (222)
Washington D.C. (77)
Washington State (732)
West Virginia (4)
Wisconsin (82)
726,775 Results for "pharmexa a s formerly m and e biotech a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
Choosing China: Akeso’s $3M Beginnings and the Rise of China’s Biotech Sector
From a small team of researchers and skipped salaries, CEO Michelle Xia has steered Akeso to become one of the most exciting companies in the industry today.
September 17, 2025
·
8 min read
·
Tristan Manalac
IPO
SPACs Line Up To Clear Biotech’s IPO Backlog
Blank check deals dwindled after a crazy 2021. Now, biotechs are starting to turn to special purpose acquisition companies again as an easy route to the public markets.
September 3, 2025
·
6 min read
·
Annalee Armstrong
Earnings
Moderna’s Bancel Nay on M&A, Yay on R&D Partnerships
It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough programs on its hands.
August 1, 2025
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
Tang Capital’s Concentra on Buyout Binge With Plenty of Biotech Fodder
After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month and seven so far this year.
August 13, 2025
·
4 min read
·
Annalee Armstrong
IPOs
MapLight Keeps Biopharma’s IPO Flame Alight To Advance Alzheimer’s, Schizophrenia Drugs
MapLight Therapeutics, the second biotech to launch a Nasdaq bid this month, is a neuro-focused company advancing treatments for Alzheimer’s disease psychosis and schizophrenia.
September 22, 2025
·
2 min read
·
Tristan Manalac
NextGen
In Biotech’s ‘Moribund’ Market, What Does It Take To Survive?
BioSpace
’s NextGen companies are rising in one of the most confounding biotech markets ever experienced. Executives sounded off on how to keep your head above water during our webinar,
Are We There Yet?
May 21, 2025
·
6 min read
·
Annalee Armstrong
Press Releases
Ori Biotech’s IRO® Platform Receives FDA Advanced Manufacturing Technology (AMT) Designation
September 4, 2025
·
3 min read
Tariffs
Biotech’s Next Phase Will Be All-American: Pitchbook
With tariffs pushing manufacturing home to the U.S., Pitchbook warns of reduced M&A activity and venture capital funding.
April 17, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
September 16, 2025
·
5 min read
Manufacturing
As Ori Wins Designation, FDA’s Advanced Manufacturing Program Nears Proof Point
Ori Biotech’s CEO said the prioritization of review by FDA, coupled to the impact of the technology, could shave up to three years off development timelines.
September 9, 2025
·
5 min read
·
Nick Paul Taylor
1 of 72,678
Next
